Fevzi Altuntaş

3.2k total citations
178 papers, 1.5k citations indexed

About

Fevzi Altuntaş is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Fevzi Altuntaş has authored 178 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Hematology, 55 papers in Oncology and 38 papers in Genetics. Recurrent topics in Fevzi Altuntaş's work include Hematopoietic Stem Cell Transplantation (47 papers), Lymphoma Diagnosis and Treatment (31 papers) and Acute Myeloid Leukemia Research (19 papers). Fevzi Altuntaş is often cited by papers focused on Hematopoietic Stem Cell Transplantation (47 papers), Lymphoma Diagnosis and Treatment (31 papers) and Acute Myeloid Leukemia Research (19 papers). Fevzi Altuntaş collaborates with scholars based in Türkiye, Cambodia and United States. Fevzi Altuntaş's co-authors include Bülent Eser, Mustafa Çetın, İ̇smail Sarı, Ali Ünal, Emre Tekgündüz, Serdal Korkmaz, Mehmet Sinan Dal, Orhan Yıldız, Tuğçe Nur Yiğenoğlu and Sinem Namdaroğlu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Fevzi Altuntaş

160 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fevzi Altuntaş Türkiye 22 409 336 246 227 215 178 1.5k
Bülent Eser Türkiye 23 543 1.3× 251 0.7× 177 0.7× 195 0.9× 317 1.5× 119 1.9k
Leylagül Kaynar Türkiye 20 423 1.0× 247 0.7× 218 0.9× 144 0.6× 247 1.1× 160 1.4k
Mustafa Çetın Türkiye 23 450 1.1× 177 0.5× 140 0.6× 246 1.1× 237 1.1× 120 1.6k
J. Hahn Germany 28 813 2.0× 364 1.1× 338 1.4× 412 1.8× 383 1.8× 92 2.4k
Ahmet Faik Öner Türkiye 21 339 0.8× 122 0.4× 327 1.3× 194 0.9× 714 3.3× 99 1.6k
Giuseppe Longo Italy 26 384 0.9× 325 1.0× 452 1.8× 213 0.9× 533 2.5× 87 2.3k
Véronique Deneys Belgium 19 414 1.0× 285 0.8× 226 0.9× 950 4.2× 324 1.5× 75 2.3k
Martin Schmidt‐Hieber Germany 26 567 1.4× 629 1.9× 509 2.1× 240 1.1× 766 3.6× 59 2.0k
Antonio Giulivi Canada 25 442 1.1× 80 0.2× 252 1.0× 174 0.8× 788 3.7× 88 2.2k
Simon Daenen Netherlands 29 1.0k 2.5× 695 2.1× 462 1.9× 262 1.2× 563 2.6× 78 2.5k

Countries citing papers authored by Fevzi Altuntaş

Since Specialization
Citations

This map shows the geographic impact of Fevzi Altuntaş's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fevzi Altuntaş with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fevzi Altuntaş more than expected).

Fields of papers citing papers by Fevzi Altuntaş

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fevzi Altuntaş. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fevzi Altuntaş. The network helps show where Fevzi Altuntaş may publish in the future.

Co-authorship network of co-authors of Fevzi Altuntaş

This figure shows the co-authorship network connecting the top 25 collaborators of Fevzi Altuntaş. A scholar is included among the top collaborators of Fevzi Altuntaş based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fevzi Altuntaş. Fevzi Altuntaş is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ulaş, Turgay, et al.. (2025). Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma. Diagnostics. 15(13). 1708–1708.
3.
Toptaş, Tayfur, Mehmet Sinan Dal, Tuğçe Nur Yiğenoğlu, et al.. (2025). Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias. Bone Marrow Transplantation. 60(6). 864–872. 1 indexed citations
4.
Hatipoğlu, Umur, et al.. (2025). Solitary Plasmacytomas: Current Status in 2025. Hematology Reports. 17(4). 32–32.
5.
Erkurt, Mehmet Ali, İlhami Berber, Sinem Namdaroğlu, et al.. (2024). Efficacy of Ruxolitinib in the management of chronic GVHD. Transfusion and Apheresis Science. 64(1). 104053–104053. 1 indexed citations
6.
Yiğenoğlu, Tuğçe Nur, Mehmet Ali Erkurt, Simten Dağdaş, et al.. (2024). What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease?. Transfusion and Apheresis Science. 64(1). 104057–104057.
7.
Yiğenoğlu, Tuğçe Nur, et al.. (2024). Is Ruxolitinib an Effective and Safe Therapy for Chronic Myeloproliferative Diseases?. Acta Oncologica Turcica. 57(1). 1–7. 1 indexed citations
8.
Dal, Mehmet Sinan, Tuğçe Nur Yiğenoğlu, Semih Başçı, et al.. (2023). Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey. Journal of Chemotherapy. 35(6). 563–569. 2 indexed citations
9.
Dal, Mehmet Sinan, Olga Meltem Akay, Özgür Mehtap, et al.. (2021). Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. Journal of Chemotherapy. 34(3). 190–198. 8 indexed citations
10.
Dal, Mehmet Sinan, et al.. (2021). Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey. Medicine. 100(41). e27458–e27458.
11.
Yiğenoğlu, Tuğçe Nur, et al.. (2021). Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma. Leukemia Research. 110. 106700–106700. 6 indexed citations
12.
Yiğenoğlu, Tuğçe Nur, et al.. (2020). Second allogeneic stem cell transplantation in acute leukemia patients: single-centre experience. SHILAP Revista de lepidopterología. 9(1). 87–96.
13.
Başçı, Semih, Mehmet Sinan Dal, Merih Kızıl Çakar, et al.. (2020). Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience. TURKISH JOURNAL OF MEDICAL SCIENCES. 51(2). 685–692. 4 indexed citations
14.
Yiğenoğlu, Tuğçe Nur, Semih Başçı, Tahir Darçın, et al.. (2020). The effect of serum vitamin B12, folate, ferritin levels and transferrin saturation on stem cell mobilization in allogeneic donors. Transfusion and Apheresis Science. 59(3). 102726–102726. 1 indexed citations
15.
Yiğenoğlu, Tuğçe Nur, Semih Başçı, Tahir Darçın, et al.. (2020). Inferior prognosis in poor mobilizing myeloma patients. Transfusion and Apheresis Science. 59(3). 102722–102722. 5 indexed citations
16.
Duygu, Fazılet, et al.. (2019). Epidemiology and mortality in bacterial bloodstream infections in patients with hematologic malignancies. The Journal of Infection in Developing Countries. 13(8). 727–735. 13 indexed citations
17.
Dal, Mehmet Sinan, et al.. (2017). Coexistence of chronic lymphocytic leukemia and multiple myeloma, do the roots of these entities originate from the same place?. Clinical Case Reports. 5(6). 1032–1033. 2 indexed citations
18.
Sipahioğlu, Murat Hayri, Fevzi Altuntaş, Leylagül Kaynar, et al.. (2009). Primary brain T-cell lymphoma concomitant with CNS tuberculosis in a kidney transplant patient.. 31(3). 256–260. 1 indexed citations
19.
Eser, Bülent, Muhammet Güven, Ali Ünal, et al.. (2005). The Role of Plasma Exchange in HELLP Syndrome. Clinical and Applied Thrombosis/Hemostasis. 11(2). 211–217. 61 indexed citations
20.
Küçük, Can, Erdoğan Sözüer, Engin Ok, Fevzi Altuntaş, & Zeki Yılmaz. (2005). Laparoscopic Versus Open Splenectomy in the Management of Benign and Malign Hematologic Diseases: A Ten-Year Single-Center Experience. Journal of Laparoendoscopic & Advanced Surgical Techniques. 15(2). 135–139. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bülent Eser Breakdown of academic impact, for papers by Leylagül Kaynar Breakdown of academic impact, for papers by Mustafa Çetın Breakdown of academic impact, for papers by J. Hahn Breakdown of academic impact, for papers by Ahmet Faik Öner Breakdown of academic impact, for papers by Giuseppe Longo Breakdown of academic impact, for papers by Véronique Deneys Breakdown of academic impact, for papers by Martin Schmidt‐Hieber Breakdown of academic impact, for papers by Antonio Giulivi Breakdown of academic impact, for papers by Simon Daenen
Rankless by CCL
2026